#drug-development

#drug-development

More than 50 percent of lung-transplant recipients experience a rejection of their new lung within five years of receiving it, yet the reason why this is such a prevalent complication has remained a medical mystery. Now, a new Northwestern Medicine study published in JCI Insight has found that, following transplant and in chronic disease states, abnormal cells emerge and "conversations" between them drive the development of lung damage and transplant rejection.

Since the mid-1940s, the National Institutes of Health has sent billions of dollars to university researchers whose work has led to the creation of scores of lifesaving treatments for a range of diseases, including cancer, Alzheimer's and heart disease. By one estimate, NIH-funded research was linked to roughly 99 percent of drugs that the U.S. Food and Drug Administration approved between 2010 and 2019.

They hoped to make tomorrow's medicines. Then came Trump. This is Camila. She's trying to figure out how cancer spreads across the body. David here is trying to cure H.I.V. And Rachael, she's trying to find new treatments for childhood brain cancer. Or at least they were. The Trump administration has so far terminated more than $1 billion in grants for the National Institutes of Health. It has fired over 1,300 employees. 1,700 canceled awards.

In the study, investigators treated 15 patients with primary aldosteronism with baxdrostat, a new drug designed to block the overproduction of aldosterone with high specificity.

The way it assimilated the information and presented it was really quite remarkable. And that's when I realized this is not just an incremental advance.

Pedro Cuatrecasas was an influential biochemist who contributed to the development of approximately 40 drugs including acyclovir for herpes and atorvastatin for cholesterol management.

The company announced that an "issue" with a batch of its flagship drug, known as briquilimab, had messed up two trial cohorts on chronic hives and a trial on asthma.

Isomorphic Labs is focused on creating a general drug design engine that applies AI across various disease areas, not just specific targets or modalities.

Working on that timescale has long stymied biologists, but the rapid evolution of time-resolved cryo-electron microscopy (TR cryo-EM) over the past several years has made it possible to reconstruct dynamic processes with near-atomic detail.

Evans' discovery of nuclear hormone receptors has transformed drug development, impacting treatments for diseases like diabetes and cancer, and underscoring the influence of biochemistry in medicine.

This material is something you would take as a capsule or liquid, but the next day it's gone because of the natural turnover of our mucosal surface in the GI tract.

Pfizer's decision to halt danuglipron development underscores the risks and complexities involved in creating new obesity treatments, particularly after significant financial investment and testing phases.